MARKET

NSPR

NSPR

Inspiremd
NASDAQ
1.150
-0.010
-0.86%
Pre Market: 1.229 +0.079 +6.89% 07:51 05/11 EDT
OPEN
1.160
PREV CLOSE
1.160
HIGH
1.180
LOW
1.120
VOLUME
8.81K
TURNOVER
0
52 WEEK HIGH
2.932
52 WEEK LOW
1.020
MARKET CAP
53.86M
P/E (TTM)
-1.5164
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NSPR last week (0504-0508)?
Weekly Report · 5h ago
InspireMD Balances Fast Growth With U.S. Setback
TipRanks · 14h ago
Insiders Make Bold Moves as InspireMD Directors Load Up on Shares
TipRanks · 2d ago
InspireMD director Scott R. Ward acquires common shares worth $102,125
PUBT · 2d ago
InspireMD director Paul Stuka acquires 7,895 shares worth $9,053.79
PUBT · 2d ago
InspireMD director Gary S. Roubin acquires $106,200 in common shares
PUBT · 2d ago
InspireMD Q1 FY26 net loss widens 22.6% to $13.69 million; revenue more than doubles to $3.4 million
PUBT · 4d ago
InspireMD presents at Bank of America Securities Global Healthcare Conference
PUBT · 4d ago
More
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Webull offers InspireMD Inc stock information, including NASDAQ: NSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NSPR stock methods without spending real money on the virtual paper trading platform.